1155877-97-6
中文名稱
D159687
英文名稱
1-(4-((3'-Chloro-6-Methoxy-[1,1'-biphenyl]-3-yl)Methyl)phenyl)urea
CAS
1155877-97-6
分子式
C21H19ClN2O2
分子量
366.84
MOL 文件
1155877-97-6.mol
更新日期
2026/07/13 11:29:14
1155877-97-6 結(jié)構(gòu)式
基本信息
中文別名
化合物D 1596871-(4-((3'-氯-6-甲氧基-[1,1'-聯(lián)苯]-3-基)甲基)苯基)脲
1-(4-((3'-氯-6-甲氧基-[1,1'-聯(lián)苯]-3-基)甲基)苯基)脲
英文別名
D159687D159687
D-159687
D 159687
1-(4-((3'-chloro-6-methoxybiphenyl-3-yl)methyl)phenyl)urea
1-(4-((3'-Chloro-6-Methoxy-[1,1'-biphenyl]-3-yl)Methyl)phenyl)urea
Urea, N-[4-[(3'-chloro-6-methoxy[1,1'-biphenyl]-3-yl)methyl]phenyl]-
物理化學(xué)性質(zhì)
沸點502.0±50.0 °C(Predicted)
密度1.263±0.06 g/cm3(Predicted)
儲存條件Sealed in dry,Room Temperature
溶解度DMSO : 150 mg/mL (408.90 mM)
酸度系數(shù)(pKa)14.48±0.50(Predicted)
形態(tài)Solid
顏色White to off-white
InChI1S/C21H19ClN2O2/c1-26-20-10-7-15(12-19(20)16-3-2-4-17(22)13-16)11-14-5-8-18(9-6-14)24-21(23)25/h2-10,12-13H,11H2,1H3,(H3,23,24,25)
InChIKeyRJJLUTWHJUDZFP-UHFFFAOYSA-N
SMILESClc1cc(ccc1)c2c(ccc(c2)Cc3ccc(cc3)NC(=O)N)OC
D159687價格(試劑級)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-15444 | D159687 D159687 | 1155877-97-6 | 1 mg | 273元 |
| 2026/06/05 | HY-15444 | D159687 D159687 | 1155877-97-6 | 5mg | 600元 |
| 2026/06/05 | HY-15444 | D159687 D159687 | 1155877-97-6 | 10mM * 1mLin DMSO | 660元 |
常見問題列表
生物活性
D159687 是一種選擇性 PDE4D 抑制劑。靶點
PDE4D
體外研究
D159687 (1 μM, 0-24?hours) induces a transient increase in CREB phosphorylation which peaked at 6?hours after treatment.
D159687 (0.01-1 μM, 6 hours) causes optimal CREB phosphorylation at 1?μM.
Western Blot Analysis
| Cell Line: | HT-22 (mouse hippocampal cell line) |
| Concentration: | 1 μM |
| Incubation Time: | 0, 1, 3, 6, 12, 24?hours |
| Result: | Induced a transient increase in CREB phosphorylation which peaked at 6?hours after treatment. |
Western Blot Analysis
| Cell Line: | HT-22 (mouse hippocampal cell line) |
| Concentration: | 0.01 μM, 0.1 μM, 1 μM |
| Incubation Time: | 6 hours |
| Result: | CREB phosphorylation was optimal at 1?μM. |
體內(nèi)研究
D159687 (0.05-5 mg/kg; oral daily for a week) shows a potential recruitment or enhancement of synaptic function with increased task difficulty in female Cynomolgus macaques.
| Animal Model: | Female Cynomolgus macaques (4–6 year old) |
| Dosage: | 0.05, 0.5, 5 mg/kg |
| Administration: | Oral daily for a week |
| Result: | A potential recruitment or enhancement of synaptic function with increased task difficulty. |